0001193125-24-139510.txt : 20240515 0001193125-24-139510.hdr.sgml : 20240515 20240515171602 ACCESSION NUMBER: 0001193125-24-139510 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aileron Therapeutics, Inc. CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 134196017 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24952570 BUSINESS ADDRESS: STREET 1: 12407 N. MOPAC EXPY. STREET 2: SUITE 250 #390 CITY: AUSTIN STATE: TX ZIP: 78758 BUSINESS PHONE: 7378021989 MAIL ADDRESS: STREET 1: 12407 N. MOPAC EXPY. STREET 2: SUITE 250 #390 CITY: AUSTIN STATE: TX ZIP: 78758 FORMER COMPANY: FORMER CONFORMED NAME: AILERON THERAPEUTICS INC DATE OF NAME CHANGE: 20071207 8-K 1 d825172d8k.htm 8-K 8-K
NASDAQ false 0001420565 0001420565 2024-05-15 2024-05-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 15, 2024

 

 

Aileron Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38130   13-4196017

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

12407 N. Mopac Expy. Suite 250 #390

Austin, Texas

   78758
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (737) 802-1989

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ALRN   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition

On May 15, 2024, Aileron Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is hereby incorporated by reference.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit

Number

    Document
99.1    Press Release, dated May 15, 2024
104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AILERON THERAPEUTICS, INC.
Date: May 15, 2024     By:  

/s/ Brian Windsor, Ph.D.

      Brian Windsor, Ph.D.
      President and Chief Executive Officer
 EX-99.1 2 d825172dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Aileron Therapeutics Reports First Quarter 2024 Financial Results and

Business Highlights

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated

Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) – Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

“In the first quarter, we made steady progress against our key priorities of advancing LTI-03 and generating data from Cohort 1in IPF,” said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. “We are encouraged that low dose LTI-03 achieved statistical significance in three out of eight biomarkers evaluated in the trial, along with promising safety and tolerability that reinforce the potential of LTI-03 to improve lung function and reverse the course of the disease. We expect to report topline results from Cohort 2 in the ongoing Phase 1b study in the third quarter of this year.”

First Quarter 2024 Highlights and Recent Updates

Financing and Management Updates

 

  •  

In May 2024, the Company closed on an underwritten registered direct offering of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock resulting in aggregate gross proceeds to the Company of approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, and excluding any proceeds that may be received from exercise of the warrants. Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68 The exercise of the warrants issued in the offering has the potential to result in additional proceeds to the Company of up to approximately $20 million.

 

  •  

In March 2024, the Company announced the appointment of Brian Windsor, Ph.D., as President and Chief Executive Officer and to the Board of Directors. Dr. Windsor previously served as the Company’s Chief Operating Officer and President, and Chief Executive Officer and director of Lung Therapeutics, Inc. (“Lung”).

Pipeline

 

  •  

Announced positive Cohort 1 data from the Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with IPF.

 

  •  

Following inhaled administration of low dose LTI-03 (2.5 mg BID, or twice daily) in twelve patients, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from three out of eight biomarkers that were statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF.

 

  •  

LTI-03 was also found to stimulate production of solRAGE, a factor indicative of type I epithelial cell health that is a critically important aspect of IPF and has gone largely unaddressed. Results show LTI-03 to be generally well-tolerated with no serious adverse events (SAEs) reported.

 

  •  

The Phase 1b study is ongoing, with topline results from the high-dose cohort expected in the third quarter of 2024.

 

  •  

On May 1, 2024, the Company hosted a pulmonary care expert call to discuss the Cohort 1 Phase 1b results of LTI-03, featuring pulmonary care expert Andreas Günther, M.D., Head of the Center for Interstitial and Rare Lung Diseases at the Justus Liebig University in Giessen, Germany. A replay of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events.

First Quarter 2024 Financial Results

 

  •  

Cash Position: Cash and cash equivalents on March 31, 2024, were $12.0 million, compared to $17.3 million on December 31, 2023. After including the net proceeds raised from the May 2024 offering and based on its current operating plan, the Company expects its existing cash and cash equivalents to fund operations into the second half of 2025.

 

  •  

Research and Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2024, were $3.5 million, compared to $1.8 million for the quarter ended March 31, 2023. The increase of $1.7 million was primarily a result of the Company’s acquisition of Lung in October 2023. During the quarter ended March 31, 2024, Aileron spent $1.1 million on clinical trials, $1.6 million on manufacturing, and $0.2 million on regulatory and development consulting as well as $0.6 million on employee and related expenses related to Lung’s programs acquired as a result of the Company’s acquisition of Lung in October 2023. These activities did not exist during the quarter ended March 31, 2023 and were offset by the termination of ALRN-6924 activities during the quarter ended March 31, 2023.

 

  •  

General and Administrative (G&A) Expenses: G&A expenses for the quarter ended March 31, 2024, were $3.7 million compared to $2.2 million for the quarter ended March 31, 2023. The increase of $1.5 million was primarily due to increased professional fees of $1.0 million and increased employee and related expenses of $0.3 million in the quarter ended March 31, 2024 as compared to the quarter ended March 31, 2023. The majority of the increase related to the acquisition of Lung, which closed in October 2023.

  •  

Net Loss: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.

About Aileron Therapeutics

Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.

Forward-Looking Statements

This press release may contain forward-looking statements of Aileron within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of the topline results from Cohort 2 of the Phase 1b study of LTI-03; the sufficiency of the Company’s cash resources; the projected cash runway of the Company; the status and plans for clinical trials, including the timing of data; future product development; and the potential commercial opportunity of LTI-03 and LTI-01. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Stock Market; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in the Company’s drug discovery; preclinical and clinical development activities; the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials or that partial results of a trial such as the Cohort 1 results from the Company’s ongoing Phase 1b trial may not be indicative of the full results of the trial; the Company’s ability to enroll patients in its clinical trials; and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the U.S. Food and Drug Administration and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to the Company’s development candidates; competition; the sufficiency of the Company’s cash resources to fund its planned activities for the periods anticipated and the Company’s ability to manage unplanned cash requirements; and general economic and market conditions; as well as the risks and uncertainties discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, which are on file with the United States Securities and Exchange Commission (the “SEC”) and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company’s view as of any date subsequent to the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations & Media Contact:

Argot Partners

aileron@argotpartners.com

212-600-1902

Aileron Therapeutics, Inc.

Balance Sheet Data

(Unaudited)

(In thousands)

 

     March 31, 2024      December 31, 2023  

Cash and cash equivalents

    $ 12,042      $ 17,313  

Working capital

      8,232        13,881  

Total assets

      99,192        106,008  

Accumulated deficit

      (295,630 )       (288,517 ) 
  

 

 

     

 

 

  

Total stockholders’ equity

    $ 44,750      $ 6,887  
  

 

 

     

 

 

  

Aileron Therapeutics, Inc.

Condensed Consolidated Statement of Operations

(Unaudited)

(In thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2024      2023  

Revenue

    $ —       $ —   
  

 

 

     

 

 

  

Operating expenses:

      

Research and development

      3,463        1,810  

General and administrative

      3,742        2,179  

Restructuring and other costs

      —         1,022  
  

 

 

     

 

 

  

Total operating expenses

      7,205        5,011  
  

 

 

     

 

 

  

Loss from operations

      (7,205 )       (5,011 ) 

Other income (expense), net

      92        232  
  

 

 

     

 

 

  

Net loss

      (7,113 )       (4,779 ) 
  

 

 

     

 

 

  

Net loss per share — basic and diluted

    $ (0.86 )     $ (1.05 ) 
  

 

 

     

 

 

  

Weighted average common shares outstanding—basic and diluted

      8,301,798        4,541,167  
  

 

 

     

 

 

  
 EX-101.SCH 3 alrn-20240515.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 alrn-20240515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 alrn-20240515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g825172g0514053126812.jpg GRAPHIC begin 644 g825172g0514053126812.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 15, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001420565
Document Type 8-K
Document Period End Date May 15, 2024
Entity Registrant Name Aileron Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38130
Entity Tax Identification Number 13-4196017
Entity Address, Address Line One 12407 N. Mopac Expy.
Entity Address, Address Line Two Suite 250
Entity Address, Address Line Three #390
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78758
City Area Code (737)
Local Phone Number 802-1989
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALRN
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d825172d8k.htm 7 alrn-20240515.xsd alrn-20240515_lab.xml alrn-20240515_pre.xml d825172d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d825172d8k.htm": { "nsprefix": "alrn", "nsuri": "http://www.aileronrx.com/20240515", "dts": { "schema": { "local": [ "alrn-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "alrn-20240515_lab.xml" ] }, "presentationLink": { "local": [ "alrn-20240515_pre.xml" ] }, "inline": { "local": [ "d825172d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-15_to_2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d825172d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-15_to_2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d825172d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aileronrx.com//20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-139510-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-139510-xbrl.zip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end XML 19 d825172d8k_htm.xml IDEA: XBRL DOCUMENT 0001420565 2024-05-15 2024-05-15 NASDAQ false 0001420565 8-K 2024-05-15 Aileron Therapeutics, Inc. DE 001-38130 13-4196017 12407 N. Mopac Expy. Suite 250 #390 Austin TX 78758 (737) 802-1989 false false false false Common Stock, $0.001 par value per share ALRN false